Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 2 for:    InDACtion
Previous Study | Return to List | Next Study

"InDACtion" vs "3+7" Induction in AML

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02172872
Recruitment Status : Recruiting
First Posted : June 24, 2014
Last Update Posted : July 12, 2018
Sponsor:
Collaborators:
Janssen Pharmaceuticals
Gruppo Italiano Malattie EMatologiche dell'Adulto
Information provided by (Responsible Party):
European Organisation for Research and Treatment of Cancer - EORTC

Brief Summary:

Older patients with acute myeloid leukemia (AML) have a small (< 10%) chance of long-term survival. Despite the treatment of elderly AML patients with intensive chemotherapy, the survival has not been improved during the last decades.

The purpose of this study is to determine whether frontline therapy with a 10-day decitabine schedule provides a better survival than standard intensive combination chemotherapy in elderly AML patients (>= 60 years).


Condition or disease Intervention/treatment Phase
Acute Myeloid Leukemia (AML) Drug: standard combination chemotherapy Drug: decitabine Phase 3

Detailed Description:
  • The overall survival (OS) of older AML patients has not been improved during the last decades with intensive chemotherapy based on cytarabine combined with an anthracycline ("3+7").
  • Next generation sequencing technology reveals that mutations in genes involved in epigenetics are frequently mutated in AML (e.g. DNMT3a), suggesting an important role of epigenetics in the pathophysiology of AML. Decitabine (given in a 5-day schedule) has been shown to be superior to low-dose Ara-C.
  • A retrospective analysis revealed that epigenetic therapy (either azacitidine or decitabine) is associated with similar survival rates as intensive chemotherapy in older patients (n=671) with newly diagnosed AML.
  • The recently published encouraging phase 2 data with the 10-day decitabine schedule suggests that decitabine results in similar CR rates compared with intensive chemotherapy. Allogeneic transplantation (alloHCT) also offers the opportunity for cure among older AML patients, therefore treatment strategies should aim to allograft older AML patients.
  • Decitabine treatment can lead to very interesting cure rates when used as "bridging" to allografting.

Based on the data summarized above, we hypothesize that decitabine at a daily dose of 20 mg/m² starting with the 10-day schedule followed by an alloHCT or by continuation of 5-days decitabine cycles is superior to conventional intensive chemotherapy in older AML patients.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 600 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: 10-day Decitabine Versus Conventional Chemotherapy ("3+7") Followed by Allografting in AML Patients ≥ 60 Years: a Randomized Phase III Study of the EORTC Leukemia Group, CELG, GIMEMA and German MDS Study Group
Study Start Date : November 2014
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : December 2019


Arm Intervention/treatment
Active Comparator: standard combination chemotherapy Drug: standard combination chemotherapy
  1. Cycle 1

    1. daunorubicin (60 mg/m²) infusion (15-30 min) for 3 days
    2. cytarabine (200 mg/m²) continuous infusion (24 hrs) for 7 days.
  2. Cycle 2

    1. daunorubicin (45 mg/m²) infusion (15-30 min) for 3 days
    2. cytarabine (200 mg/m²) continuous infusion (24 hrs) for 7 days.
  3. Cycle 3 (mini-ICE)

    1. idarubicin (8 mg/m²) infusion (15-30 min) for 3 days
    2. cytarabine (100 mg/m²) continuous infusion (24 hrs) for 5 days
    3. etoposide (100 mg/m²) infusion (1 hr) for 3 days
  4. Cycle 4 (mini-ICE) (optional)

    1. idarubicin (8 mg/m²) infusion (15-30 min) for 3 days
    2. cytarabine (100 mg/m²) continuous infusion (24 hrs) for 5 days
    3. etoposide (100 mg/m²) infusion (1 hr) for 3 days
Other Names:
  • "3+7" induction chemotherapy
  • Intensive combined chemotherapy

Experimental: decitabine Drug: decitabine
  1. Cycle 1: decitabine (20 mg/m²) infusion (1 hr) for 10 days
  2. Cycle 2

    1. if bone marrow (BM) blasts < 5%: decitabine (20 mg/m²) infusion (1 hr) for 5 days
    2. if BM blasts >= 5%: decitabine (20 mg/m²) infusion (1 hr) for 10 days
  3. Cycle 3

    1. if BM blasts < 5%: decitabine (20 mg/m²) infusion (1 hr) for 5 days
    2. if BM blasts >= 5%: decitabine (20 mg/m²) infusion (1 hr) for 10 days
  4. Cycle 4-6: decitabine (20 mg/m²) infusion (1 hr) for 5 days
  5. Continuation therapy from Cycle 7 and until 'progression or toxicity': decitabine (20 mg/m²) infusion (1 hr) for 5 days or 3 days

Note: All patients considered eligible for transplant should be consolidated with alloHCT once donor is available.

Other Name: Dacogen




Primary Outcome Measures :
  1. Overall survival (OS) [ Time Frame: 4.9 years from first patient in ]

Secondary Outcome Measures :
  1. Occurrence of adverse events (AEs) [ Time Frame: 4.9 years from first patient in ]
    The events are graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0

  2. Progression-free survival (PFS) from randomization to the date of either first progression, first relapse or death, whichever occurs first [ Time Frame: 4.9 years from first patient in ]
  3. Transplantation feasibility [ Time Frame: 4.9 years from first patient in ]
    Percentage of patients transplanted

  4. Outcome post-transplantation [ Time Frame: 4.9 years from first patient in ]
    PFS, incidence of relapse or progression, and incidence of non-relapse or progression related mortality

  5. Health economics impact of each treatment arm [ Time Frame: 4.9 years from first patient in ]
    At the end of each cycle, duration of hospitalization and number of visits (planned or related to event), number of transfusions, growth factor support and intravenous anti-infective are collected

  6. Health Related Quality of Life (HRQoL) questionnaires [ Time Frame: 4.9 years from first patient in ]
    EORTC Quality of Life Questionnaire (QLQ-C30) Elderly module (ELD14)

  7. Prognostic value of baseline physical and functional conditions on treatment outcome using geriatric assessment tools [ Time Frame: 4.9 years from first patient in ]
    Short physical performance battery (SPPB) and activities of daily living (ADL)

  8. complete response (CR/CRi) rate [ Time Frame: 4.9 years from first patient in ]
    All patients who reached complete response (CR) or complete response with incomplete marrow recovery (CRi) after the administration of protocol treatment ("3+7" or decitabine)

  9. Overall CR/CRi rate [ Time Frame: 4.9 years from first patient in ]
    All patients who reached CR or CRi, after administration of the protocol treatment ("3+7" or decitabine) or following another salvage/new treatment for AML (other than transplant)

  10. Disease-free survival (DFS) from CR or CRi [ Time Frame: 4.9 years from first patient in ]
    The time between the date of CR or CRi and the date of first relapse or death (whatever the cause), whichever occurs first



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   60 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  1. Age ≥ 60 years
  2. WHO Performance status ≤ 2
  3. Eligible for standard intensive chemotherapy
  4. Newly diagnosed AML cytopathologically confirmed to the WHO classification (up to 2 months prior to randomization)
  5. De novo or secondary AML is allowed
  6. White blood cell (WBC) count is ≤ 30x10E9/L (measured within 72 hours prior to randomization).
  7. Laboratory assessments (measured prior to randomization):

    1. serum glutamate oxaloacetate transaminase (SGOT / ASAT) and serum glutamate pyruvate transaminase (SGPT / ALAT) < 2.5 x the upper limit of normal range unless considered AML-related
    2. Total serum bilirubin < 2.5 x the upper limit of normal range unless considered AML-related or due to Gilbert's syndrome
    3. Serum creatinine < 2.5 x the upper limit of normal range unless considered AML-related
  8. Patients of reproductive potential should use adequate birth control measures, as defined by investigator, during the study treatment period and for at least 3 months after the last study treatment.
  9. Before patient registration/randomization, written informed consent must be given according to the International Conference of Harmonization good clinical practice (ICH GCP) and national/local regulations

Exclusion criteria:

  1. Presence of acute promyelocytic leukemia (APL, i.e. AML-M3 with t(15;17)(q22;q12); promyelocytic leukemia - retinoic acid receptor-alpha (PML-RARA) fusion gene and cytogenetic variants)
  2. Presence of blast crisis of chronic myeloid leukemia
  3. Presence of active central nervous system (CNS) leukemia
  4. Patients did not receive any prior treatment for AML (relapsed AML is not allowed), such as any antileukemic therapy including investigational agents and hypomethylating agents (decitabine, 5-azacytidine). Treatment with hydroxyurea (HU) is allowed to control the leukocytosis if given preferably for less than 5 days and is stopped at least two days prior to the start of any of the protocol regimens
  5. Patients received any prior treatment for myelodysplastic syndrome (MDS) or myeloproliferative neoplasms (MPN) with:

    1. hypomethylating agents (decitabine, 5-azacytidine), OR
    2. with intensive chemotherapy or transplantation within the last three years
    3. NOTE: The following treatments for previous MDS or MPN are allowed (up to one month before inclusion):

      • Growth factors, thrombomimetics, immunosuppression (cyclosporin A, steroids, antithymocyte globulin etc.), chelation, interferons, anagrelide
      • Lenalidomide, low-dose chemotherapy (low-dose melphalan, HU, low-dose cytarabine etc.), tyrosine-kinase inhibitors, histone deacetylase inhibitors (e.g. valproic acid, panobinostat etc.), mammalian target of rapamycin (mTOR) inhibitors, other experimental treatment that is not based on inhibition of deoxyribonucleic acid (DNA) methyltransferase
  6. Presence of concomitant severe cardiovascular disease which would make intensive chemotherapy impossible, i.e. uncontrolled arrhythmias requiring chronic treatment, congestive heart failure or symptomatic ischemic heart disease, reduced left ventricular function assessed by multigated acquisition (MUGA) scan or echocardiogram
  7. Presence of any malignancy (except basal and squamous cell carcinoma of the skin) for which the patient received systemic anticancer treatment within 6 months prior to randomization NOTE: Diagnosis of any previous or concomitant malignancy is thus not an exclusion criterion.
  8. Presence of active uncontrolled infection
  9. Presence of any psychological, familial, sociological or geographical condition in the opinion of the investigator potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02172872


Contacts
Layout table for location contacts
Contact: EORTC HQ +32 2 774 16 11 1301@eortc.org

  Show 63 Study Locations
Sponsors and Collaborators
European Organisation for Research and Treatment of Cancer - EORTC
Janssen Pharmaceuticals
Gruppo Italiano Malattie EMatologiche dell'Adulto
Investigators
Layout table for investigator information
Study Chair: Michael Luebbert, MD, PhD Universitaetsklinikum Freiburg, Freiburg, Germany
Principal Investigator: Gerwin G Huls, MD, PhD UMCG, Groningen, The Netherlands
Principal Investigator: Pierre W Wijermans, MD HagaZiekenhuis, the Hague, The Netherlands

Layout table for additonal information
Responsible Party: European Organisation for Research and Treatment of Cancer - EORTC
ClinicalTrials.gov Identifier: NCT02172872     History of Changes
Other Study ID Numbers: EORTC-1301
2014-001486-27 ( EudraCT Number )
First Posted: June 24, 2014    Key Record Dates
Last Update Posted: July 12, 2018
Last Verified: July 2018

Keywords provided by European Organisation for Research and Treatment of Cancer - EORTC:
Newly diagnosed
AML
Elderly
Decitabine
Transplant

Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type
Neoplasms
Leukemia, Myeloid
Decitabine
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Enzyme Inhibitors